RHY – Rhythm Biosciences Limited
3rd February 2026
Rhythm Biosciences Secures Commercial Manufacturing Agreement for ColoSTAT®
Highlights
✓ Multi-year commercial supply agreement executed with Quansys Biosciences for ColoSTAT® re-agent kit manufacturing.
✓ Agreement provides scalable manufacturing capacity to support ColoSTAT® Access Program and commercial rollout.
✓ Quansys operates ISO13485-certified manufacturing facilities with established quality systems.
✓ Supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.
✓ Agreement includes provisions for minimum order volumes and pricing framework to support anticipated operational requirements.
9th January 2026
Rhythm Biosciences establishes strategic partnership with AGRF to accelerate commercial scale-up of the Genetype service
Highlights
✓ Rhythm has partnered with Australia’s leading genomics research institute to establish Australian-based, commercial-scale processing capability for geneType™ clinical services, enabling capacity to process > 100,000 tests annually to support local customer demand.
✓ The addition of an Australian reference lab will reduce regional turnaround time, improve clinician responsiveness, and allow Australian patient samples to be processed and retained within the country.
✓ The partnership positions Rhythm to support its planned H2 2026 expansion into additional markets, leveraging AGRF as a scalable regional processing hub.
✓ Operational redundancy with dual laboratory partners (AGRF and Gene by Gene) reduces supply chain risk and supports service continuity as demand scales.
28 January
Rhythm Biosciences secures strategic US platform partnership with Cancer IQ to accelerate geneTypeTM commercial adoption
Highlights
✓ Rhythm has secured a strategic partnership with Cancer IQ, a leading US digital oncology platform used by over 65 Health Systems encompassing over 345 clinics, providing immediate market access to healthcare providers serving millions of Americans.
✓ This partnership creates a clear pathway to recurring test revenues without the cost and complexity of building a direct sales force, significantly de-risking Rhythm’s US commercialisation strategy.
✓ The integration enables streamlined ordering with automated data population, eliminating
paperwork barriers that typically slow clinical adoption and supporting scalable commercial uptake in the US.
✓ Positions Rhythm to expand recurring test volumes through embedded clinical workflows, with the platform designed to support repeat testing as patients move through cancer screening pathways.
